SCHEMBL16183253

SCHEMBL16183253

COc1cc(-c2cccc(F)c2F)cc2c(N3CC(OC)C3)nc(-c3ccccc3)nc12

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 1/20 0.41
▸ STAT6 P42226 1/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.41
▸ LMNA P02545 3/20 0.39
▸ HIF1A Q16665 3/20 0.39
▸ ABCG2 Q9UNQ0 2/20 0.39
▸ MAPT P10636 2/20 0.39
▸ HTT P42858 1/20 0.39
▸ NTSR1 P30989 4/20 0.39
▸ TSHR P16473 4/20 0.36
▸ MAPK1 P28482 3/20 0.36
▸ HSD17B10 Q99714 1/20 0.36
▸ CYP1A2 P05177 4/20 0.36
▸ CYP3A4 P08684 4/20 0.36
▸ CYP2D6 P10635 3/20 0.36
▸ USP2 O75604 2/20 0.36
▸ CLK4 Q9HAZ1 2/20 0.36
▸ SIRT1 Q96EB6 1/20 0.34
▸ TP53 P04637 2/20 0.34
▸ MAP4K1 Q92918 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14474745 0.90 MAPT (0.41) KDM4ENPSR1LMNAMAPTTSHR
SCHEMBL16183252 0.87 KDM4E (0.43) KDM4ESTAT6NPSR1LMNAHIF1A
SCHEMBL16183254 0.87 KDM4E (0.41) KDM4ESTAT6NPSR1LMNAHIF1A
SCHEMBL16184702 0.85 MAPT (0.44) KDM4ENPSR1LMNAMAPTHTT
SCHEMBL16184753 0.78 MAPT (0.48) KDM4ELMNAMAPTMAP4K1
SCHEMBL16184046 0.78 MAPT (0.45) KDM4ESTAT6NPSR1LMNAMAPT
SCHEMBL16184741 0.78 MAPT (0.47) KDM4ESTAT6NPSR1LMNAHIF1A
SCHEMBL14474741 0.78 MAPT (0.41) KDM4ENPSR1LMNAMAPTCYP1A2
SCHEMBL14474744 0.78 MAPT (0.41) KDM4ENPSR1LMNAMAPTTSHR
SCHEMBL16184745 0.78 MAPT (0.48) KDM4ESTAT6NPSR1LMNAHIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2014-10-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140315886-A1 QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE PPP2CA, PPP4C, PPP3CB KDM4E 1395/4885STAT6 2283/4885NPSR1 455/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback